Waters, BD biosciences unit agree to $17.5 billion merger
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The audit has been concluded with no major observations
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
mRNA-1010 demonstrated superior relative vaccine efficacy
Subscribe To Our Newsletter & Stay Updated